Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Rose Sheet: FDA cosmetic & supplement regulation insight

Key benefits:

Ask-the-Analyst™
Expert Analysis
Hear from news makers

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

View all content

Biomedtracker

Biomedtracker Q4 2018 Outlook Report

19 Oct 2018

Find out what’s in store for the remainder of 2018 with your copy of the Biomedtracker Q4 2018 Outlook Report Extract. This essential analysis of expected Q4 catalysts for 27 drugs is now available to you – for free. Drawn from the full report of the same name, this vital resource explores the likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) based on a drug’s phase, drug class, and disease group.

Topic Drug development landscape

Single report
Trialtrove

2017 Completed Trials

By Christine Blazynski, PhD 19 Oct 2018

As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were a total of 3,534 Phase I through Phase III/IV. The nearly 700 trials terminated in 2017 were not included in this analysis.

Topic Clinical trials

View white paper
Citeline, Trialtrove

Rheumatoid Arthritis - Old and New Approaches Shifting the Treatment Paradigm

By Laura Runkel 19 Oct 2018

Explore the current and future outlook for rheumatoid arthritis (RA) treatments. Such treatments remain ineffective for the 33% of RA sufferers who are or become unresponsive to treatment, resulting in a high interest in RA drug development to address this unmet need in the marketplace.

View white paper
Scrip

Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?

By Jessica Merrill 18 Oct 2018

PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads.

Topic Drug approval Drug review

View article
Scrip

Not To Be Sniffed At: Dupixent Success In Rhinosinusitis Could Open Up Large Additional Market

By Alexandra Shimmings 18 Oct 2018

On the brink of an expanded US approval for asthma, Sanofi/Regeneron’s interleukin-4 receptor blocker Dupixent has produced positive topline Phase III data in a lucrative third indication, rhinosinusitis with nasal polyps.

Topic Influenza virus

View article
Biomedtracker

Pharma Partnering Trends Revealed Whitepaper

12 Oct 2018

Make the most of BIO-Europe 2018 with essential partnering information from Informa Pharma Intelligence. Our insightful whitepaper, Pharma Partnering Trends Revealed: 2018 Edition, contains critical information on the landscape for biotech partnerships, and is now available for you to download – free.

View white paper
Scrip

A Life In Genes - Scrip Award Winner Sir Gregory Winters Speech

03 Oct 2018

The 2015 Scrip Lifetime Achievement Award was given to Sir Gregory Winter, Master of Trinity College, Cambridge (UK). Founder of Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics, he is best known for his pioneering research into humanizing antibodies. His findings led to the development of the first human antibody, Humira (adalimumab), until very recently the world's top-selling drug.

Topic Drug development landscape Cancer

View article
Scrip

Interview - Greg Winters Story So Far

By Jo Shorthouse 03 Oct 2018

Biochemist Greg Winter has scientifically contributed to some of the pharmaceutical industry's biggest commercial and therapeutic success stories. He tells Scrip how he feels about being labelled a pioneer and why he is still wary of the boardroom.

Topic Cancer

View article
Scrip

IPO Update: Returns Sag As Seven More Biopharmas Go Public In September

By Mandy Jackson 03 Oct 2018

The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.

Topic Drug development landscape

View article
Scrip

Momenta Is Exiting Biosimilars Is That A Bellwether For Biosimilar Sentiment

By Jessica Merrill 03 Oct 2018

CEO Craig Wheeler talked toScripabout the challenging biosimilar market dynamics and the company's decision to end most biosimilar drug development. The path to value creation in biosimilars is not clear, he said.

Topic Biosimilars Drug development landscape

View article
Scrip

AstraZenecas PACIFIC Update Bolsters Imfinzis Lead In Stage III Lung Cancer

By Emily Hayes 26 Sep 2018

Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.

Topic Cancer

View article
Scrip

Tecentriq's Small-Cell Lung Cancer Success Takes Edge Off Roche's IO Position

By Emily Hayes 26 Sep 2018

Roche's combination of Tecentriq with chemotherapy is ahead of rivals in first-line SCLC and has been filed with the US FDA.

Topic Cancer

View article
Rose Sheet

CIR Recalculates Parabens Safety Margins; Will Expert Panel’s Confidence Be Shaken?

By Ryan Nelson 21 Sep 2018

The Cosmetic Ingredient Review’s newly figured margins of safety for single- and multi-paraben use in cosmetic products are dramatically lower than previous MOSs that informed the Expert Panel’s 2008 “safe as used” conclusions. Whether the panel still deems the MOSs sufficiently protective is the question going into the group’s Sept. 24-25 meeting.

View article
Scrip

ICON CEO: CROs Must Be Aware Of Threat Posed By Big Tech

By Jo Shorthouse 20 Sep 2018

ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of running one of the industry’s largest CROs.

Topic Company analysis

View article
Scrip

Tildrakizumab Set For Europe Debut - Can It Make A Dent?

By Anju Ghangurde 20 Sep 2018

Almirall's Ilumetri, licensed from Sun Pharma, has been cleared by the European Commission, upping the competition quotient in the psoriasis market and pitting the product directly against Johnson & Johnson's Tremfya.

Topic BioPharmaceutical

View article

Latest headlines

Scrip

19 Oct 2018

Pharma Q3 Results Preview: Biogen, Gilead, Celgene

Link
Scrip

19 Oct 2018

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing

Link
Scrip

19 Oct 2018

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Link
Scrip

19 Oct 2018

Every Little Helps: Shire Product Advances Fortify Takeda's Bid

Link
Scrip

18 Oct 2018

UCB Pushes On With Potential Myasthenia Gravis Therapy, But Competition Looms

Link
Scrip

18 Oct 2018

Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy

Link
Scrip

18 Oct 2018

CDMO Space In Focus As Piramal Mulls Sale

Link
Scrip

18 Oct 2018

AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

Link
Scrip

18 Oct 2018

Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory

Link
Scrip

18 Oct 2018

Eight Things To Know From Novartis' Third Quarter Call

Link
Scrip

18 Oct 2018

Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects

Link
Scrip

17 Oct 2018

Executives On The Move: New CEOs At Perrigo And SanBio, CMOs At CardioVascular BioTherapeutics And Harpoon Therapeutics, And A Retirement At BTG

Link
Scrip

17 Oct 2018

Tie-Up Moves Kangstem's Novel Stem Cell Therapy Towards Globalization

Link
Scrip

16 Oct 2018

Vertex’s Danish Reimbursement Deal Brings Budget Predictability

Link
Scrip

16 Oct 2018

Pfizer Expands In Breast Cancer With Talazoparib Approval

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Get ahead with in-depth pharmaceutical competitive intelligence

​Master the marketplace

Relevant products

Below are the Product List

Rose Sheet: FDA cosmetic & supplement regulation insight

Datamonitor Healthcare: data analysis and insight

Scrip: industry news and insights

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store

Master the marketplace